Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society
Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE Phase 1/2 Trial in People Living with DMD44
VanadiumCorp Completes Soil Geochemical Survey at its Lac Laura Gold-Copper Property; 314 Samples Submitted to AGAT Laboratories for Analysis
